欧狄沃诞生记：改写抗癌历史的重磅疗法(6)

从1992年药物靶点的偶然发现起步，到2014年创新药的首度全球获批，再到2018年造福广大中国患者，这款突破性免疫疗法已经走过了26年的漫长道路。在这里，我们向基础科学家、新药研发人员、以及医药监管部门致以崇高敬意。正是你们的努力、坚守、与创新，才让诸多中国癌症患者迎来了改写生命的全新机遇。

[转载出处：www.ii77.com]

[转载出处：www.ii77.com]

参考资料：

[1] Drug Helps Defense System Fight Cancer, Retrieved August 25, 2018, from http://www.nytimes.com/2012/06/02/business/drug-helps-immune-system-fight-cancer.html

[2] W Decker et al., (2017), Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models, Frontiers in Immunology, DOI:  10.3389/fimmu.2017.00829

[3] Variolation, Retrieved August 25, 2018, from http://en.wikipedia.org/wiki/Variolation

[4] E McCarthy, The Toxins of William B. Coley and the Treatment of Bone and Soft-Tissue Sarcomas, The Iowa Orthopedic Journal, 2006; 26: 154–158.

[5] A Kumanogoh et al., (2010), The study of cytokines by Japanese researchers: a historical perspective, International Immunology, DOI: http://doi.org/10.1093/intimm/dxq022

[6] T Okazaki et al., (2007), PD-1 and PD-1 ligands: from discovery to clinical application, International Immunology, DOI: http://doi.org/10.1093/intimm/dxm057

[7] Y Ishida et al., (1992), Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death, EMBO Journal, vol. 11 pg. 3887

[8] CRI Names Winners of Top Scientific Prize, Retrieved August 26, 2018, from http://www.cancerresearch.org/blog/september-2014/cri-names-winners-of-top-scientific-prize

[9] T Okazaki et al., (2007), PD-1 and PD-1 ligands: from discovery to clinical application. International Immunology. 19(7):813-824.

[10] H Dong et al., (1999), B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature Medicine. 5(12) 1365-1369.

[11] H Dong et al., (2002), Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nature Medicine. 8(8):793-799.

[12] D Leach et al., (1996), Enhancement of antitumor immunity by ctla-4 blockade, Science, Mar 22;271(5256):1734-6.

[13] Y Iwai et al., (2002), Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade, PNAS, DOI: http://doi.org/10.1073/pnas.192461099

[14] Five-year follow-upfrom the CA209-003 study of nivolumab in previously treated advanced non-smallcell lung cancer: Clinical characteristics of long-term survivors. 2017 AACR Annual Meeting. Abstract CT077. Presented April 3, 2017.

[15] Wu YL, Lu S, Cheng Y, et al. AACR 2018; Abstract CT114.

[16] El-Khoueiry AB, Sangro B, Yau T, et al. nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017. Jun 24;389(10088):2492-2502

[17] Kang YK, Boku N, Satoh T, Ryu MH, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Dec 2; 390(10111): 2461-2471.

本文来自药明康德微信团队，欢迎转发到朋友圈，谢绝转载到其他..；如有开设白名单需求，请在文章底部留言；如有其他合作需求，请联系wuxi_media@wuxiapptec.com